Reteplase

Summary

Reteplase (CHEMBL2107885) is an approved enzyme (ATC B01AD07); indicated across 6 conditions including thrombotic disease and myocardial infarction.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: B01AD07
• Indications: 6 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107885
Name	Reteplase
Type	Enzyme
Max phase	4
ATC	B01AD07

Also known as: BM 06.022, BM-06.022, BM-06022, Ecokinase, Rapilysin, Retavase, Reteplasa, Reteplase, recombinant, Retevase, RETEPLASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419
myocardial infarction	4	MONDO:0005068	EFO:0000612
heart failure	4	MONDO:0005252	EFO:0003144
ST-elevation myocardial infarction	4	MONDO:0041656	EFO:0008585

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
stroke disorder	2	MONDO:0005098	EFO:0000712

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00178620	PHASE4	COMPLETED	Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
NCT00806403	PHASE4	COMPLETED	Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction
NCT05900674	PHASE2	WITHDRAWN	Endovascular Stroke Treatment And Reteplase Protocol

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).